US 12,291,576 B2
Anti-CD45 antibodies and conjugates thereof
Rahul Palchaudhuri, Somerville, MA (US); Bradley R. Pearse, Watertown, MA (US); Hillary Adams, Medford, MA (US); Sean McDonough, Littleton, MA (US); Michael Cooke, Boston, MA (US); and Anthony Boitano, Newton, MA (US)
Assigned to Vor Biopharma Inc., Cambridge, MA (US)
Filed by Vor Biopharma Inc., Cambridge, MA (US)
Filed on Apr. 29, 2021, as Appl. No. 17/244,856.
Application 17/244,856 is a continuation of application No. PCT/US2019/058971, filed on Oct. 30, 2019.
Claims priority of provisional application 62/807,582, filed on Feb. 19, 2019.
Claims priority of provisional application 62/774,006, filed on Nov. 30, 2018.
Claims priority of provisional application 62/753,002, filed on Oct. 30, 2018.
Prior Publication US 2021/0371524 A1, Dec. 2, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 38/12 (2006.01); A61K 39/00 (2006.01); A61K 47/68 (2017.01); A61P 35/02 (2006.01)
CPC C07K 16/289 (2013.01) [A61K 38/12 (2013.01); A61K 47/6831 (2017.08); A61K 47/6849 (2017.08); A61P 35/02 (2018.01); A61K 2039/505 (2013.01)] 26 Claims
 
1. An isolated anti-CD45 antibody, or antigen binding portion thereof, comprising:
(i) a heavy chain comprising a variable region comprising a CDR1 having the amino acid sequence as set forth in SEQ ID NO: 2, a CDR2 having the amino acid sequence as set forth in SEQ ID NO: 3, a CDR3 having the amino acid sequence as set forth in SEQ ID NO: 4, and comprising a light chain comprising a variable region comprising a CDR1 having the amino acid sequence as set forth in SEQ ID NO: 6, a CDR2 having the amino acid sequence as set forth in SEQ ID NO: 7, a CDR3 having the amino acid sequence as set forth in SEQ ID NO: 8;
(ii) a heavy chain comprising a variable region comprising a CDR1 having the amino acid sequence as set forth in SEQ ID NO: 10, a CDR2 having the amino acid sequence as set forth in SEQ ID NO: 11, a CDR3 having the amino acid sequence as set forth in SEQ ID NO: 12, and comprising a light chain comprising a variable region comprising a CDR1 having the amino acid sequence as set forth in SEQ ID NO: 14, a CDR2 having the amino acid sequence as set forth in SEQ ID NO: 15, a CDR3 having the amino acid sequence as set forth in SEQ ID NO: 16; or
(iii) a heavy chain comprising a variable region comprising a CDR1 having the amino acid sequence as set forth in SEQ ID NO: 18, a CDR2 having the amino acid sequence as set forth in SEQ ID NO: 19, a CDR3 having the amino acid sequence as set forth in SEQ ID NO: 20, and comprising a light chain comprising a variable region comprising a CDR1 having the amino acid sequence as set forth in SEQ ID NO: 22, a CDR2 having the amino acid sequence as set forth in SEQ ID NO: 23, a CDR3 having the amino acid sequence as set forth in SEQ ID NO: 24.